Invested in Paralos Bioscience, a programmable phage-drug conjugate company, on 23-Jun-2026.
Paralos Bioscience is developing engineered M13 bacteriophage carriers that separate targeting from payload loading, aiming to improve drug delivery by localizing exposure and reducing development risks
Paralos Bioscience is developing engineered M13 bacteriophage carriers that separate targeting from payload loading, aiming to improve drug delivery by localizing exposure and reducing development risks.